Summary
BeOne Medicines Ltd. (ONC) demonstrates a strong liquidity position as of December 31, 2017, with substantial holdings in cash and cash equivalents ($239.6 million) and short-term investments ($597.9 million). The company prioritizes capital preservation and liquidity in its investment strategy, primarily holding high-quality U.S. treasury and agency securities, along with time deposits. While a hypothetical 100 basis point change in interest rates could impact the fair value of its investment portfolio by approximately $2.3 million, ONC believes this is not material to its financial condition or results of operations. The company acknowledges exposure to foreign currency exchange rate risks, particularly with the Chinese Renminbi (RMB), which is not freely convertible. Fluctuations in the RMB against the U.S. dollar could impact the U.S. dollar equivalent of its earnings and the cost of converting currencies for operations or distributions. Despite these risks, ONC currently does not utilize derivative financial instruments for hedging and maintains that its disclosure controls and internal financial reporting controls were effective as of December 31, 2017.
Financial Highlights
53 data points| Revenue | $238.39M |
| Cost of Revenue | $4.97M |
| Gross Profit | $233.41M |
| R&D Expenses | $269.02M |
| SG&A Expenses | $62.60M |
| Operating Expenses | $336.84M |
| Operating Income | -$98.46M |
| Net Income | -$93.11M |
| EPS (Basic) | $-0.17 |
| Shares Outstanding (Basic) | 543.19M |
Key Highlights
- 1Strong liquidity with $239.6 million in cash and cash equivalents and $597.9 million in short-term investments as of December 31, 2017.
- 2Investment strategy focused on capital preservation and liquidity, primarily in U.S. treasury/agency securities and time deposits.
- 3Estimated potential impact of a 100 basis point interest rate change on the investment portfolio is $2.3 million, considered not material.
- 4Exposure to foreign currency exchange rate risk, particularly with the non-freely convertible RMB, which can affect reported earnings and currency conversion costs.
- 5No significant direct foreign exchange risk currently identified, and no derivative financial instruments used for hedging.
- 6Effective disclosure controls and procedures and internal control over financial reporting as of December 31, 2017.
- 7Acquisition of Celgene Shanghai (renamed BeiGene Pharmaceutical (Shanghai)) on August 31, 2017, noted as excluded from internal control effectiveness assessment for the year-end.